We are live on ! Find out more
PBM

Propel Bio Management Portfolio holdings

AUM $191M
1-Year Est. Return 102.42%
This Fund
S&P 500
This Quarter Est. Return
-0.95%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$159M
AUM Growth
+$41.5M
Cap. Flow
+$58M
Cap. Flow %
36.57%
Top 10 Hldgs %
58.29%
Holding
42
New
22
Increased
6
Reduced
6
Closed
4

Top Buys

Rank Stock Value
1
UPB
Upstream Bio Inc
UPB
+$6.15M
2
CORT icon
Corcept Therapeutics
CORT
+$5.53M
3
DCTH icon
Delcath Systems
DCTH
+$5.24M
4
VOR icon
Vor Biopharma
VOR
+$4.44M
5
OBIO icon
Orchestra BioMed
OBIO
+$3.82M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$3.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$2.15M
3
RGNX icon
Regenxbio
RGNX
+$1.68M
4
IVA
Inventiva
IVA
+$1.68M
5
OCS icon
Oculis Holding
OCS
+$1.34M

Sector Composition

Rank Sector Weight
1 Healthcare 80.98%
2 Energy 19.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PAGP icon
1
Plains GP Holdings
PAGP
$5.54B
$30.2M 19.02%
1,272,360
– –
ACHV icon
2
Achieve Life Sciences
ACHV
$834M
$11.4M 7.17%
3,786,425
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$743M
$9.35M 5.9%
841,272
+100,354
+14% +$1.27M
DCTH icon
4
Delcath Systems
DCTH
$567M
$9.16M 5.77%
979,698
+541,189
+123% +$5.24M
CORT icon
5
Corcept Therapeutics
CORT
$12.3B
$6.02M 3.8%
+147,828
New +$5.53M
ABEO icon
6
Abeona Therapeutics
ABEO
$339M
$6.01M 3.79%
1,329,899
+499,119
+60% +$2.5M
VOR icon
7
Vor Biopharma
VOR
$1.34B
$5.59M 3.52%
+314,543
New +$4.44M
KYTX icon
8
Kyverna Therapeutics
KYTX
$518M
$5.59M 3.52%
644,421
-22,245
-3% -$185K
MIST icon
9
Milestone Pharmaceuticals
MIST
$144M
$5.08M 3.2%
4,118,321
– –
CLDX icon
10
Celldex Therapeutics
CLDX
$3.07B
$4.14M 2.61%
131,364
-22,936
-15% -$625K
CMPS
11
Compass Pathways
CMPS
$1.9B
$4.12M 2.6%
742,049
-119,729
-14% -$805K
VRDN icon
12
Viridian Therapeutics
VRDN
$2.61B
$4.09M 2.58%
210,163
-72,368
-26% -$2.15M
IVA
13
Inventiva
IVA
$1.11B
$3.99M 2.52%
724,678
-275,322
-28% -$1.68M
SABS icon
14
SAB Biotherapeutics
SABS
$345M
$3.89M 2.45%
1,012,790
+359,909
+55% +$1.44M
OBIO icon
15
Orchestra BioMed
OBIO
$311M
$3.83M 2.41%
+896,701
New +$3.82M
FDMT icon
16
4D Molecular Therapeutics
FDMT
$810M
$3.58M 2.26%
+380,420
New +$3.31M
OCS icon
17
Oculis Holding
OCS
$678M
$3.28M 2.07%
122,223
-50,616
-29% -$1.34M
OCUL icon
18
Ocular Therapeutix
OCUL
$2.28B
$3.23M 2.03%
+382,375
New +$3.64M
UPB
19
Upstream Bio Inc
UPB
$366M
$3.1M 1.95%
+341,779
New +$6.15M
AQST icon
20
Aquestive Therapeutics
AQST
$630M
$2.95M 1.86%
+710,988
New +$2.89M
EYPT icon
21
EyePoint Inc
EYPT
$386M
$2.79M 1.76%
+215,825
New +$3.23M
TRVI icon
22
Trevi Therapeutics
TRVI
$2.39B
$2.65M 1.67%
+223,802
New +$2.51M
ZVRA icon
23
Zevra Therapeutics
ZVRA
$686M
$2.64M 1.66%
282,418
+218,735
+343% +$1.97M
IMUX icon
24
Immunic
IMUX
$210M
$2.62M 1.65%
+234,478
New +$2.1M
CHRS icon
25
Coherus Oncology
CHRS
$218M
$2.41M 1.52%
+1,420,550
New +$2.52M
1
2

Similar funds

CFG
Capital Financial Group Greenwood Village, Colorado $191M AUM
MWM
Magnolia Wealth Management Dothan, Alabama $191M AUM 17.58% 1-Year Est. Return
ALWM
Andrews Lucia Wealth Management Danville, California $191M AUM 24.94% 1-Year Est. Return
PFA
Pillar Financial Advisors Louisville, Kentucky $191M AUM 21.21% 1-Year Est. Return
LKWM
Lee-Kelleher Wealth Management Fulton, Maryland $191M AUM 28.48% 1-Year Est. Return
NWM
Navigoe Wealth Management Redondo Beach, California $191M AUM 25.21% 1-Year Est. Return
AA
Atmos Advisory Pittsburgh, Pennsylvania $191M AUM 12.84% 1-Year Est. Return
MCA
Martin Capital Advisors San Antonio, Texas $191M AUM 42.42% 1-Year Est. Return

Propel Bio Management's Q1 2026 Portfolio in Review

As of Q1 2026, Propel Bio Management held 42 positions worth $159M, up 35% from $117M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Propel Bio Management deployed $58M of net new capital in Q1 2026, opening 22 new positions and adding to 6 existing holdings. Its largest new stake was Upstream Bio Inc: 341,779 shares worth $3.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 79% a quarter earlier, followed by Energy.

On the sell side, the largest reduction was Viridian Therapeutics, an estimated $2.15M trimmed.

  • Propel Bio Management's largest Q1 2026 buy was Upstream Bio Inc: 341,779 shares worth $3.1M.
  • Propel Bio Management added most to Delcath Systems in Q1 2026, an estimated $5.24M increase.
  • Propel Bio Management's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $2.15M.
  • Propel Bio Management fully exited Nektar Therapeutics in Q1 2026, selling an estimated $3.5M.
  • Propel Bio Management's ten largest holdings make up 58% of its $159M portfolio in Q1 2026.
  • Propel Bio Management opened 22 new positions and closed 4 in Q1 2026.
  • Propel Bio Management's portfolio value rose 35% quarter-over-quarter to $159M.

Based on Propel Bio Management's 13F filing for Q1 2026, filed 14 May 2026.